Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression

• Kumiko Koyama ,

  Roles Conceptualization, Investigation, Methodology, Validation, Visualization, Writing – review & editing

  * E-mail: koyama.kumiko.hv@daiichisankyo.co.jp

  Affiliation Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan

  https://orcid.org/0000-0002-2090-7860

  ⨯
• Hirokazu Ishikawa,

  Roles Investigation, Methodology, Writing – review & editing

  Affiliation Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan

  ⨯
• Manabu Abe,

  Roles Investigation, Methodology, Validation, Visualization, Writing – review & editing

  Affiliation Specialty Medicine Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan

  ⨯
• Yoshinobu Shiose,

  Roles Conceptualization, Writing – review & editing

  Affiliation Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan

  ⨯
• Suguru Ueno,

  Roles Conceptualization, Writing – review & editing

  Affiliation Cell Therapy Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan

  ⨯
• Yang Qiu,

  Roles Writing – review & editing

  Affiliation Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America

  ⨯
• Kenji Nakamaru,

  Roles Supervision, Writing – review & editing

  Affiliation Translational Science Department I, Daiichi Sankyo Co., Ltd., Tokyo, Japan

  ⨯
• Masato Murakami

  Roles Supervision, Writing – review & editing

  Affiliation Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America

  ⨯